Considering the frequent lineage switches and sensitivity to both ALL- and AML-directed schemes, a uniform strategy directed at both lymphoid and myeloid lineages or at hematopoietic stem cells may be better for <i>TCF3-ZNF384</i>-positive leukemia. This evidence concerns the gene ZNF384 and acute myeloid leukemia.